Little Green Pharma Ltd. (AU:LGP)
Australian Market

Little Green Pharma Ltd. (LGP) Income Statement


Little Green Pharma Ltd. Income Statement

Last quarter (Q4 2021), Little Green Pharma Ltd.'s total revenue was AU$―. In Q4, Little Green Pharma Ltd.'s net income was AU$―. See Little Green Pharma Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 22Jun 21Jun 20
Total Revenue
AU$ ―AU$ 10.28MAU$ 7.00MAU$ 2.20M
Cost of Revenue
AU$ ―AU$ 5.01MAU$ 1.23MAU$ 1.05M
Gross Profit
AU$ ―AU$ 5.27MAU$ 5.78MAU$ 1.15M
Operating Expense
AU$ ―AU$ 25.67MAU$ 10.67MAU$ 8.75M
Operating Income
AU$ ―AU$ -20.40MAU$ -4.90MAU$ -7.60M
Net Non Operating Interest Income Expense
AU$ ―AU$ -512.04KAU$ -52.26KAU$ -352.97K
Other Income Expense
AU$ ―AU$ 1.86MAU$ 28.87MAU$ -1.37M
Pretax Income
AU$ ―AU$ -18.05MAU$ 24.60MAU$ -9.32M
Tax Provision
AU$ ―AU$ 0.00AU$ 0.00AU$ 0.00
Earnings From Equity Interest Net Of Tax
AU$ ―---
Net Income Common Stockholders
AU$ ―AU$ -18.29MAU$ 24.60MAU$ -9.32M
Basic EPS
AU$ ―AU$ -0.08AU$ 0.16AU$ -0.07
Diluted EPS
AU$ ―AU$ -0.08AU$ 0.15AU$ -0.07
Basic Average Shares
AU$ ―AU$ 235.92MAU$ 153.72MAU$ 127.95M
Diluted Average Shares
AU$ ―AU$ 235.92MAU$ 165.79MAU$ 127.95M
Dividend Per Share
AU$ ―---
Total Operating Income As Reported
AU$ ―---
Reported Normalized Basic E P S
AU$ ―---
Reported Normalized Diluted E P S
AU$ ―---
Rent Expense Supplemental
AU$ ―---
Total Expenses
AU$ ―---
Net Income From Continuing And Discontinued Operation
AU$ ―AU$ -18.29MAU$ 24.60MAU$ -9.32M
Normalized Income
AU$ ―AU$ -18.05MAU$ 24.60MAU$ -9.32M
Interest Expense
AU$ ―AU$ 543.53KAU$ 91.54KAU$ 327.37K
AU$ ―AU$ -17.51MAU$ 24.70MAU$ -8.99M
AU$ ―AU$ -16.50MAU$ 25.38MAU$ -8.80M
Currency in AUD

Little Green Pharma Ltd. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis